Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association
Reporter: Aviva Lev-Ari, PhD, RN
- AHA Policy Statement
Forecasting the Impact of Heart Failure in the United States
A Policy Statement From the American Heart Association
-
Paul A. Heidenreich, MD, MS, FAHA, Chair,
- Nancy M. Albert, PhD, RN, FAHA,
- Larry A. Allen, MD, MHS,
- David A. Bluemke, MD, PhD, FAHA,
- Javed Butler, MD, MPH, FAHA,
- Gregg C. Fonarow, MD, FAHA,
- John S. Ikonomidis, MD, PhD, FRCS(C), FAHA,
- Olga Khavjou, MA,
- Marvin A. Konstam, MD,
- Thomas M. Maddox, MD, MSc,
- Graham Nichol, MD, MPH, FRCP(C), FAHA,
- Michael Pham, MD, MPH,
- Ileana L. Piña, MD, MPH, FAHA,
- Justin G. Trogdon, PhD and
- on behalf of the American Heart Association Advocacy Coordinating Committee:
- Council on Arteriosclerosis,
- Thrombosis and Vascular Biology,
- Council on Cardiovascular Radiology and Intervention,
- Council on Clinical Cardiology,
- Council on Epidemiology and Prevention, and
- Stroke Council
Abstract
Background—Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than for any other medical condition. With the aging of the population, the impact of HF is expected to increase substantially.
Methods and Results—We estimated future costs of HF by adapting a methodology developed by the American Heart Association to project the epidemiology and future costs of HF from 2012 to 2030 without double counting the costs attributed to comorbid conditions. The model assumes that HF prevalence will remain constant by age, sex, and race/ethnicity and that rising costs and technological innovation will continue at the same rate.
By 2030,
- >8 million people in the United States (1 in every 33) will have HF.
- Between 2012 and 2030, real (2010$) total direct medical costs of HF are projected to increase from $21 billion to $53 billion.
- Total costs, including indirect costs for HF, are estimated to increase from $31 billion in 2012 to $70 billion in 2030.
- If one assumes all costs of cardiac care for HF patients are attributable to HF (no cost attribution to comorbid conditions), the 2030 projected cost estimates of treating patients with HF will be 3-fold higher ($160 billion in direct costs).
Conclusions—The estimated prevalence and cost of care for HF will increase markedly because of aging of the population. Strategies to prevent HF and improve the efficiency of care are needed.
Key Words:
http://circheartfailure.ahajournals.org/content/early/2013/04/24/HHF.0b013e318291329a.abstract
15 page PDF, at the below link
REFERENCE
Four Policy Statement From the American Heart Association
-
AHA Policy StatementForecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association
- Paul A. Heidenreich,
- Nancy M. Albert,
- Larry A. Allen,
- David A. Bluemke,
- Javed Butler,
- Gregg C. Fonarow,
- John S. Ikonomidis,
- Olga Khavjou,
- Marvin A. Konstam,
- Thomas M. Maddox,
- Graham Nichol,
- Michael Pham,
- Ileana L. Piña,
- and Justin G. Trogdon
Circ Heart Fail. 2013;published online before print April 24 2013,doi:10.1161/HHF.0b013e318291329a
…American Heart Association. Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations…and improve the efficiency of care are needed. AHA Scientific Statements|heart failure| -
Select this article
Special ReportStatement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States
- Michael A. Acker,
- Francis D. Pagani,
- Wendy Gattis Stough,
- Douglas L. Mann,
- Mariell Jessup,
- Robert Kormos,
- Mark S. Slaughter,
- Timothy Baldwin,
- Lynne Stevenson,
- Keith D. Aaronson,
- Leslie Miller,
- David Naftel,
- Clyde Yancy,
- Joseph Rogers,
- Jeffrey Teuteberg,
- Randall C. Starling,
- Bartley Griffith,
- Steven Boyce,
- Stephen Westaby,
- Elizabeth Blume,
- Peter Wearden,
- Robert Higgins,
- and Michael Mack
Circ Heart Fail. 2013;6:e1-e11, published online before print November 12 2012,doi:10.1161/HHF.0b013e318279f6b5
…wolterskluwer.com . Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations…of Mechanically Assisted Circulatory Support.AHA Scientific Statements|heart-assist device|heart failure|BTC… -
Select this article
Special ReportStatement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary
- Michael A. Acker,
- Francis D. Pagani,
- Wendy Gattis Stough,
- Douglas L. Mann,
- Mariell Jessup,
- Robert Kormos,
- Mark S. Slaughter,
- Timothy Baldwin,
- Lynne Stevenson,
- Keith D. Aaronson,
- Leslie Miller,
- David Naftel,
- Clyde Yancy,
- Joseph Rogers,
- Jeffrey Teuteberg,
- Randall C. Starling,
- Bartley Griffith,
- Steven Boyce,
- Stephen Westaby,
- Elizabeth Blume,
- Peter Wearden,
- Robert Higgins,
- and Michael Mack
Circ Heart Fail. 2013;6:145-150, published online before print November 12 2012,doi:10.1161/HHF.0b013e318279f55d
…wolterskluwer.com . Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations…of Mechanically Assisted Circulatory Support.AHA Scientific Statements|heart-assist device|heart failure| Background… -
Select this article
ACCF/AHA/HFSA Data and Survey ReportACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation: A Report of the ACCF Heart Failure and Transplant Committee, AHA Heart Failure and Transplantation Committee, and Heart Failure Society of America
- Mariell Jessup,
- Nancy M. Albert,
- David E. Lanfear,
- JoAnn Lindenfeld,
- Barry M. Massie,
- Mary Norine Walsh,
- and Mark J. Zucker
Circ Heart Fail. 2011;4:378-387, published online before print April 4 2011,doi:10.1161/HHF.0b013e3182186210
…hired for a given practice volume. These survey results are an initial step in developing such standards. AHA Scientific Statements|heart failure|heart transplant|mechanical circulatory support device|staffing profile| 1. Introduction…
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.